Viking Therapeutics: An Equally Important Catalyst Ahead

Biotech Beast9.19K FollowersFollow5ShareSavePlay(12min)CommentsSummaryViking Therapeutics completed enrollment of the VK2735 maintenance study in January and is set to report results in Q3'26.The maintenance study will provide multiple efficacy and tolerability insights on a range of VK2735 regimes, including maintenance dosing with oral VK2735.VKTX maintains a strong cash position ($706M at 2025 year-end), with the company's CFO noting cash burn of $60–90M per quarter going forward.Key risks include competitive readouts (notably LLY's retatrutide), possible fundraising before data, and potential delays in VANQUISH-2 enrollment. wildpixel/iStock via Getty Images Viking Therapeutics (VKTX) has already completed enrollment of its VANQUISH-1 study of VK2735 in obesity, and its VANQUISH-2 study in type 2 diabetes/obesity is set to complete enrollment this quarter. Those studies will take 78 weeksThis article was written byBiotech Beast9.19K FollowersFollowScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.